Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors

Oncologist

Volumn 17, Issue 4, 2012, Pages 550-554

  Bezabeh, Shewit ^a   Mackey, Ann Corken ^a   Kluetz, Paul ^a   Jappar, Dilara ^a   Korvick, Joyce ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Drug interaction; Methotrexate; Proton pump inhibitor

Indexed keywords

BICARBONATE PLUS OMEPRAZOLE; BREAST CANCER RESISTANCE PROTEIN; ESOMEPRAZOLE; ESOMEPRAZOLE PLUS NAPROXEN; FOLINIC ACID; LANSOPRAZOLE; MEGESTROL; METHOTREXATE; NAPROXEN; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SUCRALFATE;

CANCER CHEMOTHERAPY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEMATOLOGIC DISEASE; HUMAN; LIVER DYSFUNCTION; LOW DRUG DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; MYOPATHY; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG INTERACTIONS; DRUG LABELING; HUMANS; METHOTREXATE; PROTON PUMP INHIBITORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84860126496     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0431     Document Type: Review

References (21)

1. Xanodyne Pharmacal, Inc. Methotrexate Sodium for Injection, revised October 2003. Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm, accessed March 30, 2011.
2. Holmboe L, Andersen AM, Mørkrid L et al. High-dose methotrexate chemotherapy: Pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol 2012;73:106-114.
3. Welage LS. Pharmacologic properties of proton pump inhibitors. Pharmacotherapy 2003;23:74S-80S.
4. Kessler DA. Introducing Med Watch. A new approach to reporting medication and device adverse effects and production problems. JAMA 1993;269: 2765-2768.
5. Brinker A, Beitz J. Use of a spontaneous adverse drug events database for identification of unanticipated drug benefits. Clin Pharmacol Ther 2002;71:99-102.
6. Reid T, Yuen A, Catolico M et al. Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother Pharmacol 1993;33:82-84.
7. Beorlegui B, Aldaz A, Ortega A et al. Potential interaction between methotrexate and omeprazole. Ann Pharmacother 2000;34:1024-1027.
8. Trôger U, Stötzel B, Martens-Lobenhoffer J et al. Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate. BMJ 2002;324:1497.
9. Bauters TG, Verlooy J, Robays H et al. Interaction between methotrexate and omeprazole in an adolescent with leukemia: A case report. Pharm World Sci 2008;30:316-318.
10. Huls M, Brown CD, Windass AS et al. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int 2008;73:220-225.
11. Breedveld P, Zelcer N, Pluim D et al. Mechanisms of the pharmacokinetic interaction between methotrexate and benzimidazoles: Potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 2004;64: 5804-5811.
12. Suzuki K, Doki K, Homma M et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 2008;67:44-49.
13. Joerger M, Huitema A, van den Bongard HJ et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol 2006;62:71-80.
14. Santucci R, Levêque D, Kemmel V et al. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. Anticancer Res 2010;30:963-965.
15. Santucci R, Levéque D, Lescoute A et al. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors. Anticancer Res 2010;30:3807-3810.
16. Whelan J, Hoare D, Leonard P. Omeprazole does not alter plasma methotrexate clearance. Cancer Chermother Pharmacol 1999;44:88-89.
17. Vakily M, Amer F, Kukulka MJ et al. Coadministration of lansoprazole and naproxen does not affect the pharmcokinetic profile of methotrexate in adult patients with rheumatoid arthritis. J Clin Pharmacol 2005;45:1179-1186.
18. U.S. Food and Drug Administration. Methotrexate Sodiumfor Injection Product Label. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/011719s117lbl.pdf, accessed October 24, 2011.
19. Rogers AS, Israel E, Smith CR et al. Physician knowledge, attitudes, and behavior related to reporting of adverse drug events. Arch Intern Med 1998; 148:1596-1600.
20. Reuben MA, Starr FL, Birmingham S et al. Characterization of a renal H,K ATPase α subunit mRNA found to be identical with gastric H,K ATPase mRNA. Gastroenterology 1993;104(suppl):177.
21. Osther PJ, Rasmussen L, Pedersen SA. A double-blind placebo-controlled trial of omeprazole on urinary pH in healthy subjects. Int Urol Nephrol 1992;24:229-231.